SCHEMBL3098656

SCHEMBL3098656

Fc1ccc(OCCCCBr)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
DRD2 P14416 2/20 0.49
DRD4 P21917 2/20 0.49
DRD3 P35462 2/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7388659 0.98 MEN1 (0.54) MEN1KMT2ALMNAHTTUSP2
SCHEMBL15922927 0.98 MEN1 (0.54) MEN1KMT2ALMNAHTTUSP2
SCHEMBL6750345 0.98 MEN1 (0.54) MEN1KMT2ALMNAHTTUSP2
SCHEMBL27517121 0.94 MEN1 (0.49) MEN1KMT2ALMNAHTTUSP2
SCHEMBL1427333 0.93 DRD2 (0.50) MEN1KMT2ALMNAHTTUSP2
SCHEMBL11615899 0.89 KCNA3 (0.55) HRH3DRD3L3MBTL1CYP2D6GAA
SCHEMBL10338308 0.89 MEN1 (0.60) MEN1KMT2ALMNAHTTUSP2
SCHEMBL27515741 0.88 MEN1 (0.46) MEN1KMT2ALMNAHTTUSP2
SCHEMBL118043 0.86 CYP1A2 (0.50) MEN1KMT2ALMNAHTTUSP2
SCHEMBL9361193 0.86 LSS (0.59) LMNAHRH3KDM4ESMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025217552-A1 2-(TERT-BUTYL)-4-METHYLPHENYL APPENDED 1,4-DIAZEPANE BASED NOVEL TFEB ACTIVATING COMPOUNDS AS AUTOPHAGY MODULATORS FOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE (AD) MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2025-10-16 WO disclosed
CN-108440278-B Dicarboxy chalcone compound and its application in preparing anti-inflammatory medicine 中国计量大学 2021-01-12 CN disclosed
CN-102617494-B Triazole compound containing vinyl ether structure and preparation method and application thereof NANJING TECH UNIVERSITY (CN) 2014-10-29 CN disclosed
EP-2726457-A1 INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES Adamed sp. z o.o. (PL) 2014-05-07 EP disclosed
US-20140121216-A1 INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES ADAMED SP. Z O.O. (PL) 2014-05-01 US disclosed
CN-103649048-A Indoleamine derivatives for the treatment of central nervous system diseases ADAMED SP ZOO 2014-03-19 CN disclosed
US-8367702-B2 Quinolone derivative ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
WO-2013001499-A1 INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES ADAMED SP. Z O.O. (PL) 2013-01-03 WO disclosed
US-20100256113-A1 QUINOLONE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-10-07 US disclosed
CN-101801933-A quinolone derivative ASTELLAS PHARMA INC 2010-08-11 CN disclosed
EP-0527079-B1 N-(isoquinolein-5-yl)-sulfonyl azacycloalkanes, their process of preparation and pharmaceutical compositions containing them ADIR (FR) 1996-10-23 EP disclosed
WO-1996012718-A1 NOUVELLES 2-[1-(φ-PHENOXYALCOYLPIPERIDIN-4-YL)AMINOMETHYLENE]-2H-BENZOFURAN-3-ONES SUBSTITUEES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE PIERRE FABRE MEDICAMENT (FR) 1996-05-02 WO disclosed
EP-0672031-A1 CATECHOL DIETHERS AS SELECTIVE PDE IV? INHIBITORS PFIZER INC. (US) 1995-09-20 EP disclosed
WO-1994012461-A1 CATECHOL DIETHERS AS SELECTIVE PDEIV INHIBITORS PFIZER INC. (US) 1994-06-09 WO disclosed
US-5298503-A Cardiovascular ADIR ET COMPAGNIE (FR) 1994-03-29 US disclosed
US-5208243-A Analgesics ADIR ET COMPAGNIE (FR) 1993-05-04 US disclosed
EP-0527079-A1 N-(isoquinolein-5-yl)-sulfonyl azacycloalkanes, their process of preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1993-02-10 EP disclosed
EP-0526342-A1 Isoquinolin-5yl-sulphonamides, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1993-02-03 EP disclosed
US-4139620-A HYPOTENSIVE AGENTS A. H. ROBINS COMPANY, INC. (US) 1979-02-13 US disclosed
US-4096331-A HYPOTENSIVE A. H. ROBINS COMPANY, INCORPORATED (US) 1978-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121216-A1 INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES TPH1, TPH2, HTR3A MEN1 361/4885KMT2A 1540/4885LMNA 1729/4885
US-20100256113-A1 QUINOLONE DERIVATIVE NQO1, NQO2, NADK MEN1 4763/4885KMT2A 1299/4885LMNA 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.